NCT00005072View on ClinicalTrials.gov

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

April 30, 2003

Study Completion Date

April 30, 2003

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

Leuvectin

1000 ug of Leuvectin injected intratumorally

Trial Locations (2)

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

Sponsors

Lead Sponsor

Vical
All Listed Sponsors
collaborator

Jonsson Comprehensive Cancer Center

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Vical

INDUSTRY